Report cover image

Global Anti-VEGF Therapeutic Market 2025 by Manufacturers, Regions, Type and Application, Forecast to 2031

Publisher GlobalInfoResearch
Published Apr 28, 2025
Length 101 Pages
SKU # GFSH19992745

Description

According to our (Global Info Research) latest study, the global Anti-VEGF Therapeutic market size was valued at US$ 969 million in 2024 and is forecast to a readjusted size of USD 1512 million by 2031 with a CAGR of 6.6% during review period.

Anti–vascular endothelial growth factor therapy, also known as anti-VEGF therapy or medication, is the use of medications that block vascular endothelial growth factor.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

This report is a detailed and comprehensive analysis for global Anti-VEGF Therapeutic market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.

Key Features:

Global Anti-VEGF Therapeutic market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031

Global Anti-VEGF Therapeutic market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031

Global Anti-VEGF Therapeutic market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031

Global Anti-VEGF Therapeutic market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2020-2025

The Primary Objectives in This Report Are:

To determine the size of the total market opportunity of global and key countries

To assess the growth potential for Anti-VEGF Therapeutic

To forecast future growth in each product and end-use market

To assess competitive factors affecting the marketplace

This report profiles key players in the global Anti-VEGF Therapeutic market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Regeneron Pharmaceuticals, Bayer, Novartis, Roche, Biogen, Pfizer, Coherus BioSciences, Amgen, Bausch Health Companies, Viatris, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Market Segmentation

Anti-VEGF Therapeutic market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type
Aflibercept (Eylea)
Ranibizumab (Lucentis)
Brolucizumab (Beovu)
Others

Market segment by Application
Macular Edema
Diabetic Retinopathy
Retinal Vein Occlusion
Age-related Macular Degeneration
Others

Major players covered
Regeneron Pharmaceuticals
Bayer
Novartis
Roche
Biogen
Pfizer
Coherus BioSciences
Amgen
Bausch Health Companies
Viatris

Market segment by region, regional analysis covers

North America (United States, Canada, and Mexico)

Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)

Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)

South America (Brazil, Argentina, Colombia, and Rest of South America)

Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)

The content of the study subjects, includes a total of 15 chapters:

Chapter 1, to describe Anti-VEGF Therapeutic product scope, market overview, market estimation caveats and base year.

Chapter 2, to profile the top manufacturers of Anti-VEGF Therapeutic, with price, sales quantity, revenue, and global market share of Anti-VEGF Therapeutic from 2020 to 2025.

Chapter 3, the Anti-VEGF Therapeutic competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4, the Anti-VEGF Therapeutic breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2020 to 2031.

Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2020 to 2031.

Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2020 to 2025.and Anti-VEGF Therapeutic market forecast, by regions, by Type, and by Application, with sales and revenue, from 2026 to 2031.

Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.

Chapter 13, the key raw materials and key suppliers, and industry chain of Anti-VEGF Therapeutic.

Chapter 14 and 15, to describe Anti-VEGF Therapeutic sales channel, distributors, customers, research findings and conclusion.

Table of Contents

101 Pages
1 Market Overview
1.1 Product Overview and Scope
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Anti-VEGF Therapeutic Consumption Value by Type: 2020 Versus 2024 Versus 2031
1.3.2 Aflibercept (Eylea)
1.3.3 Ranibizumab (Lucentis)
1.3.4 Brolucizumab (Beovu)
1.3.5 Others
1.4 Market Analysis by Application
1.4.1 Overview: Global Anti-VEGF Therapeutic Consumption Value by Application: 2020 Versus 2024 Versus 2031
1.4.2 Macular Edema
1.4.3 Diabetic Retinopathy
1.4.4 Retinal Vein Occlusion
1.4.5 Age-related Macular Degeneration
1.4.6 Others
1.5 Global Anti-VEGF Therapeutic Market Size & Forecast
1.5.1 Global Anti-VEGF Therapeutic Consumption Value (2020 & 2024 & 2031)
1.5.2 Global Anti-VEGF Therapeutic Sales Quantity (2020-2031)
1.5.3 Global Anti-VEGF Therapeutic Average Price (2020-2031)
2 Manufacturers Profiles
2.1 Regeneron Pharmaceuticals
2.1.1 Regeneron Pharmaceuticals Details
2.1.2 Regeneron Pharmaceuticals Major Business
2.1.3 Regeneron Pharmaceuticals Anti-VEGF Therapeutic Product and Services
2.1.4 Regeneron Pharmaceuticals Anti-VEGF Therapeutic Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
2.1.5 Regeneron Pharmaceuticals Recent Developments/Updates
2.2 Bayer
2.2.1 Bayer Details
2.2.2 Bayer Major Business
2.2.3 Bayer Anti-VEGF Therapeutic Product and Services
2.2.4 Bayer Anti-VEGF Therapeutic Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
2.2.5 Bayer Recent Developments/Updates
2.3 Novartis
2.3.1 Novartis Details
2.3.2 Novartis Major Business
2.3.3 Novartis Anti-VEGF Therapeutic Product and Services
2.3.4 Novartis Anti-VEGF Therapeutic Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
2.3.5 Novartis Recent Developments/Updates
2.4 Roche
2.4.1 Roche Details
2.4.2 Roche Major Business
2.4.3 Roche Anti-VEGF Therapeutic Product and Services
2.4.4 Roche Anti-VEGF Therapeutic Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
2.4.5 Roche Recent Developments/Updates
2.5 Biogen
2.5.1 Biogen Details
2.5.2 Biogen Major Business
2.5.3 Biogen Anti-VEGF Therapeutic Product and Services
2.5.4 Biogen Anti-VEGF Therapeutic Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
2.5.5 Biogen Recent Developments/Updates
2.6 Pfizer
2.6.1 Pfizer Details
2.6.2 Pfizer Major Business
2.6.3 Pfizer Anti-VEGF Therapeutic Product and Services
2.6.4 Pfizer Anti-VEGF Therapeutic Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
2.6.5 Pfizer Recent Developments/Updates
2.7 Coherus BioSciences
2.7.1 Coherus BioSciences Details
2.7.2 Coherus BioSciences Major Business
2.7.3 Coherus BioSciences Anti-VEGF Therapeutic Product and Services
2.7.4 Coherus BioSciences Anti-VEGF Therapeutic Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
2.7.5 Coherus BioSciences Recent Developments/Updates
2.8 Amgen
2.8.1 Amgen Details
2.8.2 Amgen Major Business
2.8.3 Amgen Anti-VEGF Therapeutic Product and Services
2.8.4 Amgen Anti-VEGF Therapeutic Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
2.8.5 Amgen Recent Developments/Updates
2.9 Bausch Health Companies
2.9.1 Bausch Health Companies Details
2.9.2 Bausch Health Companies Major Business
2.9.3 Bausch Health Companies Anti-VEGF Therapeutic Product and Services
2.9.4 Bausch Health Companies Anti-VEGF Therapeutic Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
2.9.5 Bausch Health Companies Recent Developments/Updates
2.10 Viatris
2.10.1 Viatris Details
2.10.2 Viatris Major Business
2.10.3 Viatris Anti-VEGF Therapeutic Product and Services
2.10.4 Viatris Anti-VEGF Therapeutic Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
2.10.5 Viatris Recent Developments/Updates
3 Competitive Environment: Anti-VEGF Therapeutic by Manufacturer
3.1 Global Anti-VEGF Therapeutic Sales Quantity by Manufacturer (2020-2025)
3.2 Global Anti-VEGF Therapeutic Revenue by Manufacturer (2020-2025)
3.3 Global Anti-VEGF Therapeutic Average Price by Manufacturer (2020-2025)
3.4 Market Share Analysis (2024)
3.4.1 Producer Shipments of Anti-VEGF Therapeutic by Manufacturer Revenue ($MM) and Market Share (%): 2024
3.4.2 Top 3 Anti-VEGF Therapeutic Manufacturer Market Share in 2024
3.4.3 Top 6 Anti-VEGF Therapeutic Manufacturer Market Share in 2024
3.5 Anti-VEGF Therapeutic Market: Overall Company Footprint Analysis
3.5.1 Anti-VEGF Therapeutic Market: Region Footprint
3.5.2 Anti-VEGF Therapeutic Market: Company Product Type Footprint
3.5.3 Anti-VEGF Therapeutic Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 Consumption Analysis by Region
4.1 Global Anti-VEGF Therapeutic Market Size by Region
4.1.1 Global Anti-VEGF Therapeutic Sales Quantity by Region (2020-2031)
4.1.2 Global Anti-VEGF Therapeutic Consumption Value by Region (2020-2031)
4.1.3 Global Anti-VEGF Therapeutic Average Price by Region (2020-2031)
4.2 North America Anti-VEGF Therapeutic Consumption Value (2020-2031)
4.3 Europe Anti-VEGF Therapeutic Consumption Value (2020-2031)
4.4 Asia-Pacific Anti-VEGF Therapeutic Consumption Value (2020-2031)
4.5 South America Anti-VEGF Therapeutic Consumption Value (2020-2031)
4.6 Middle East & Africa Anti-VEGF Therapeutic Consumption Value (2020-2031)
5 Market Segment by Type
5.1 Global Anti-VEGF Therapeutic Sales Quantity by Type (2020-2031)
5.2 Global Anti-VEGF Therapeutic Consumption Value by Type (2020-2031)
5.3 Global Anti-VEGF Therapeutic Average Price by Type (2020-2031)
6 Market Segment by Application
6.1 Global Anti-VEGF Therapeutic Sales Quantity by Application (2020-2031)
6.2 Global Anti-VEGF Therapeutic Consumption Value by Application (2020-2031)
6.3 Global Anti-VEGF Therapeutic Average Price by Application (2020-2031)
7 North America
7.1 North America Anti-VEGF Therapeutic Sales Quantity by Type (2020-2031)
7.2 North America Anti-VEGF Therapeutic Sales Quantity by Application (2020-2031)
7.3 North America Anti-VEGF Therapeutic Market Size by Country
7.3.1 North America Anti-VEGF Therapeutic Sales Quantity by Country (2020-2031)
7.3.2 North America Anti-VEGF Therapeutic Consumption Value by Country (2020-2031)
7.3.3 United States Market Size and Forecast (2020-2031)
7.3.4 Canada Market Size and Forecast (2020-2031)
7.3.5 Mexico Market Size and Forecast (2020-2031)
8 Europe
8.1 Europe Anti-VEGF Therapeutic Sales Quantity by Type (2020-2031)
8.2 Europe Anti-VEGF Therapeutic Sales Quantity by Application (2020-2031)
8.3 Europe Anti-VEGF Therapeutic Market Size by Country
8.3.1 Europe Anti-VEGF Therapeutic Sales Quantity by Country (2020-2031)
8.3.2 Europe Anti-VEGF Therapeutic Consumption Value by Country (2020-2031)
8.3.3 Germany Market Size and Forecast (2020-2031)
8.3.4 France Market Size and Forecast (2020-2031)
8.3.5 United Kingdom Market Size and Forecast (2020-2031)
8.3.6 Russia Market Size and Forecast (2020-2031)
8.3.7 Italy Market Size and Forecast (2020-2031)
9 Asia-Pacific
9.1 Asia-Pacific Anti-VEGF Therapeutic Sales Quantity by Type (2020-2031)
9.2 Asia-Pacific Anti-VEGF Therapeutic Sales Quantity by Application (2020-2031)
9.3 Asia-Pacific Anti-VEGF Therapeutic Market Size by Region
9.3.1 Asia-Pacific Anti-VEGF Therapeutic Sales Quantity by Region (2020-2031)
9.3.2 Asia-Pacific Anti-VEGF Therapeutic Consumption Value by Region (2020-2031)
9.3.3 China Market Size and Forecast (2020-2031)
9.3.4 Japan Market Size and Forecast (2020-2031)
9.3.5 South Korea Market Size and Forecast (2020-2031)
9.3.6 India Market Size and Forecast (2020-2031)
9.3.7 Southeast Asia Market Size and Forecast (2020-2031)
9.3.8 Australia Market Size and Forecast (2020-2031)
10 South America
10.1 South America Anti-VEGF Therapeutic Sales Quantity by Type (2020-2031)
10.2 South America Anti-VEGF Therapeutic Sales Quantity by Application (2020-2031)
10.3 South America Anti-VEGF Therapeutic Market Size by Country
10.3.1 South America Anti-VEGF Therapeutic Sales Quantity by Country (2020-2031)
10.3.2 South America Anti-VEGF Therapeutic Consumption Value by Country (2020-2031)
10.3.3 Brazil Market Size and Forecast (2020-2031)
10.3.4 Argentina Market Size and Forecast (2020-2031)
11 Middle East & Africa
11.1 Middle East & Africa Anti-VEGF Therapeutic Sales Quantity by Type (2020-2031)
11.2 Middle East & Africa Anti-VEGF Therapeutic Sales Quantity by Application (2020-2031)
11.3 Middle East & Africa Anti-VEGF Therapeutic Market Size by Country
11.3.1 Middle East & Africa Anti-VEGF Therapeutic Sales Quantity by Country (2020-2031)
11.3.2 Middle East & Africa Anti-VEGF Therapeutic Consumption Value by Country (2020-2031)
11.3.3 Turkey Market Size and Forecast (2020-2031)
11.3.4 Egypt Market Size and Forecast (2020-2031)
11.3.5 Saudi Arabia Market Size and Forecast (2020-2031)
11.3.6 South Africa Market Size and Forecast (2020-2031)
12 Market Dynamics
12.1 Anti-VEGF Therapeutic Market Drivers
12.2 Anti-VEGF Therapeutic Market Restraints
12.3 Anti-VEGF Therapeutic Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
13 Raw Material and Industry Chain
13.1 Raw Material of Anti-VEGF Therapeutic and Key Manufacturers
13.2 Manufacturing Costs Percentage of Anti-VEGF Therapeutic
13.3 Anti-VEGF Therapeutic Production Process
13.4 Industry Value Chain Analysis
14 Shipments by Distribution Channel
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Anti-VEGF Therapeutic Typical Distributors
14.3 Anti-VEGF Therapeutic Typical Customers
15 Research Findings and Conclusion
16 Appendix
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us